Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% Equity-to-Asset is 0.82 as of Dec. 2025, which is 1% above its 10-year median of 0.81. The stock has 3 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Verici Dx ranks better than 84.83% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Verici Dx's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $6.51 Mil. Verici Dx's Total Assets for the quarter that ended in Dec. 2025 was $7.94 Mil.
Therefore, Verici Dx's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.82.
The historical rank and industry rank for Verici Dx's Equity-to-Asset or its related term are showing as below:
VRCDF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48 Med: 0.81 Max: 0.97
Current: 0.82
During the past 6 years, the highest Equity to Asset Ratio of Verici Dx was 0.97. The lowest was 0.48. And the median was 0.81.
VRCDF's Equity-to-Asset is ranked better than 84.83% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs VRCDF: 0.82
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Verici Dx Equity-to-Asset Related Terms
Verici Dx Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Verici Dx's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRCDF vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Verici Dx's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Verici Dx's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Verici Dx's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (VRCDF) has a Equity-to-Asset of 0.82 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Verici Dx and its competitors. This is near median its historical median of 0.81. Over the past decade, Verici Dx's Equity-to-Asset has ranged from 0.48 to 0.97. According to the industry distribution chart, Verici Dx ranks #32 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Verici Dx's Equity-to-Asset too high?
Verici Dx's current Equity-to-Asset of 0.82 is near median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 0.97. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Verici Dx's value of 0.82 is 39% above this industry median. Based on the distribution chart, Verici Dx ranks #32 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #32 out of 211 companies for Equity-to-Asset. This places Verici Dx in the top 15% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.59. Verici Dx's value of 0.82 is 39% above this benchmark. Historically, Verici Dx's own Equity-to-Asset has ranged from 0.48 to 0.97 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 0.59, Verici Dx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current Equity-to-Asset of 0.82 is 39% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current Equity-to-Asset of 0.82. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.81 and 39% above the Medical Diagnostics & Research industry median of 0.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Verici Dx (VRCDF), the current Equity-to-Asset is 0.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
